Skip to main navigation
Skip to search
Skip to main content
Discover Research at University College Cork Home
Search content at Discover Research at University College Cork
Home
Profiles
Research units
Research output
Activities
Prizes
Datasets
Impacts
Courses
Press/Media
Treatment of HER2-positive breast cancer
Maria Cristina Figueroa-Magalhães
, Danijela Jelovac
,
Roisin M. Connolly
, Antonio C. Wolff
Johns Hopkins University
Research output
:
Contribution to journal
›
Review article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Treatment of HER2-positive breast cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Targeted Therapy
100%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
100%
Trastuzumab
100%
Chemotherapy
100%
Metastatic Carcinoma
66%
Overall Survival
66%
Breast Cancer
33%
Pertuzumab
33%
Progression Free Survival
33%
Therapeutic Management
33%
Disease Free Survival
33%
Epidermal Growth Factor Receptor 2
33%
Gamma Urogastrone
33%
Tyrosine-Kinase Inhibitor
33%
Lapatinib
33%
Tumor
33%
Antibody Therapy
33%
Trastuzumab Emtansine
33%
Pharmacology, Toxicology and Pharmaceutical Science
Trastuzumab
100%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
100%
Chemotherapy Regimen
100%
Overall Survival
66%
Breast Cancer
33%
Pertuzumab
33%
Protein Tyrosine Kinase Inhibitor
33%
Progression Free Survival
33%
Disease Free Survival
33%
Epidermal Growth Factor Receptor 2
33%
Gamma Urogastrone
33%
Lapatinib
33%
Trastuzumab Emtansine
33%
Immunology and Microbiology
Trastuzumab
100%
Overall Survival
66%
Tyrosine
33%
Progression Free Survival
33%
Disease Free Survival
33%
Gamma Urogastrone
33%
Pertuzumab
33%
Phosphotransferase
33%
Kinase
33%
Trastuzumab Emtansine
33%